WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL

27th October 2008 MELBOURNE, Australia, October 27 /PRNewswire/ -- MuriGen Therapeutics today announced that its collaboration with CSL for the development of a new class of drugs that target arthritis and other inflammatory diseases has been restructured. The collaboration was initially established in February 2006 by MuriGen Therapeutics and Zenyth Therapeutics Limited (now part of CSL Limited) and is developing therapeutic antibodies that inhibit the activity of the cytokine granulocyte colony... more

Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR

8th October 2008 SAN DIEGO, October 8 /PRNewswire/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN), a company developing innovative therapeutics for the treatment of viral infections and cancer, today provided an update on its ongoing development programs. The company also announced that it will initiate a corporate restructuring that will extend the company's financial resources to pursue near-term corporate development opportunities, sale of specific programs, M&A and alternative financial arrangements to... more

Merck Serono and ZymoGenetics Restructure Partnership

3rd September 2008 GENEVA, Switzerland, September 3 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and ZymoGenetics, Inc. (NASDAQ: ZGEN), Seattle, United States, today announced a restructuring of their partnership. With respect to the ongoing development of atacicept, an investigational drug for the treatment of various autoimmune diseases and B-cell malignancies, ZymoGenetics has exercised its contractual right to convert to a worldwide royalty license. By making this election,... more

Most viewed

Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR

Merck Serono and ZymoGenetics Restructure Partnership

WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL